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Aims: A deficit in parvalbumin (PV) neurons is found in schizophrenia and several 
animal models of the disease. In this preliminary study, we determined whether one 
such model, phencyclidine (PCP) administration, results in changes in DNA 
methylation in the rat PV gene (Pvalb) promoter. Methods: DNA from hippocampus 
and prefrontal cortex (PFC) from rats, which 6 weeks previously received either 
2mg/kg PCP or vehicle for 7 days, underwent bisulphite pyrosequencing to determine 
methylation. Results: PCP administration induced significantly greater methylation at 
one of two Pvalb CpG sites in both PFC and hippocampus, while no significant 
difference was found in Long Interspersed Nucleotide Element-1, a global measure of 
DNA methylation. Conclusion: Subchronic PCP administration results in a specific 
hypermethylation in the Pvalb promoter which may contribute to PV deficits in this 
animal model of psychosis.  
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 The NMDA receptor antagonist phencyclidine (PCP) has been widely used in 
the investigation and modelling of psychotic illness. Sub-chronic administration of 
PCP to animals can induce brain metabolic and neurochemical changes [1] as well as 
behaviours [2] that mimic aspects of schizophrenia. Furthermore, this regime can also 
produce enduring deficits in several neurochemical markers that are also diminished 
in the brain in schizophrenia. These include the calcium binding protein parvalbumin 
(PV), which is expressed in a subgroup of GABAergic neurons, and in schizophrenia 
demonstrates reductions in frontal cortical regions [3] and, particularly profoundly, in 
the hippocampus [4]. Equivalent losses, typically greater than 50%, of PV-
immunoreactive (PV-IR) cells, are also seen in the rat hippocampus following sub-
chronic PCP [2]. 
Deficits in immunostaining for PV-positive neurons have also been seen in other 
animal models that mimic some of the behavioural and also, in some models, the 
aetiological characteristics of schizophrenia. These include isolation rearing [5], 
administration of neonatal endotoxin [6] and prenatal methylazoxymethanol (MAM) 
[7] in rats, as well as following other psychotogenic drugs including ketamine [8,9] 
and amphetamine [10].  
The pathogenic mechanisms underlying these deficits in PV are unclear, although 
PCP can also induce decreases in PV gene (Pvalb) expression [1,11]. We have 
speculated whether the PV deficit might relate to epigenetic changes induced by such 
pharmacological and environmental influences. One epigenetic factor is that of DNA 
methylation occurring at cytosine residues in CpG sequences; within promoter 
sequences this methylation can have major effects on gene expression [12]. There is 
evidence for dynamic effects on methylation of the mouse PV gene promoter 
sequence associated with manganese-induced neurotoxic damage [13]; we 
hypothesised that changes in methylation of this sequence might relate to PV deficits 
in schizophrenia and its animal models. In this preliminary study we have determined 
the methylation status of CpG methylation sites within the equivalent sequence in 
frontal cortical (PFC) and hippocampal tissue from rats that had received subchronic 
PCP. The results were compared with a global measure of DNA methylation, that of 
Long Interspersed Nucleotide Element-1 (LINE-1) [14,15]. We used the novel object 
recognition (NOR) paradigm to assess the efficacy of the treatment regime to induce 
cognitive deficits prior to the post-mortem analysis. 
 
2. Material and Methods 
 Female Lister-hooded rats (200-230g) were housed in groups of 4-5 under 
standard laboratory conditions under a 12hr light: dark cycle, lights on at 0700hr. Rats 
were randomly assigned to two groups and either received vehicle, (distilled water, 
i.p.) or phencyclidine hydrochloride (PCP, 2 mg/kg, i.p. twice daily for 7-days) 
dissolved in distilled water. Behavioural testing was carried out in the light phase. 
Rats were tested in the novel object recognition (NOR) paradigm and for locomotor 
activity 6 weeks after the last dose of PCP. Following the behavioural testing the 
brains were removed, flash frozen in isopentane and stored at -70%. These studies 
were carried out in accordance with the Animals Scientific Procedures Act (UK, 
1986) and were approved by the University of Manchester ethical review panel. 
The NOR paradigm has been described in detail elsewhere [16]. Briefly, following 
habituation to the test box, the rats are given an initial acquisition trial during which 
the animals are allowed to explore two identical objects for 3 min. After a 1 min 
interval when the animals are removed, one object is replaced with a novel object and 
the animals allowed to explore the objects again for 3 min. The exploration times of 
each object in each trial are recorded on video for subsequent blind scoring. NOR was 
determined by the discrimination index (DI) in the retention trial, calculated as: (tn – 
tf) / (tn + tf) where tn and tf are times spent exploring the novel and familiar objects 
respectively. Data are expressed as mean ± SEM. (n= 9 per group) and were analysed 
by a one way ANOVA.  
 Genomic DNA was extracted from PFC and hippocampal tissue using 
QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA), was bisulphite-modified to 
convert unmethylated cytosine residues to uracil using the EpiTec Fast DNA 
Bisulphite Kit (Qiagen) with a calculated mean conversion of 99%. We identified a 
previously-studied [13] DNA sequence in the 5’ region of the rat Pvalb gene (Rnor6.0, 
Chromosome 7, bases 119441848 - 119441803) that contained likely transcription 
factor binding sequences, and developed a pyrosequencing method for determination 
of methylation at the Pvalb CpG sites within this sequence following bisulphite 
reaction.  
The region containing the sequence of interest in the Pvalb promoter was amplified to 
yield an amplicon of 149 bases using primers: 5'-
TAAGGGGTTTTATTGGGGTAGA-3' (forward) and 5'[btn]-
ATCTAAAATACCACCAACAAACACTA-3' (reverse) (Eurofins MWG Operon).  
For LINE-1, a sequence of 4 CpGs was amplified [17] by PCR primers, as follows: 
5'-TTGTTGTAAGAAAGTTGTTTGGTGAGTT-3' (forward) and 5'[btn]-
ACCTCAAAAATACCCACCTAACC -3' (reverse) (Eurofins MWG Operon). Mean 
values for methylation were calculated and used as a measure of global methylation. 
  PCR reactions were carried out with 20 ng bisulphite-converted DNA using 
the PyroMark PCR kit in a final volume of 25 µl containing 12.5 µl 1x PyroMark 
PCR Master Mix, 2.5 µl 1x CoralLoad Concentrate, 1 µl of each primer in a final 
concentration of 0.05 µM, 7 µl RNase-free water. Amplification conditions were as 
follows: 95°C for 15 min, 45 cycles of 94°C for 30 s, 56°C for 30 s and 72°C for 30 s, 
finally, 72°C for 10 min. Methylation status of the Pvalb promoter sequence was 
determined with a PyroMark Q24 pyrosequencer (Qiagen UK) using 15–20 µl PCR 
product and a sequencing primer, 5'- GTAGAGGTTGGTTAGTAT-3' (Eurofins 
MWG Operon). LINE-1 methylation was determined with a sequencing primer 5'- 
GGTGAGTTTGGGATA-3' (Eurofins MWG Operon). Pyrosequence setup and data 
reading were conducted by PyroMark Q24 2.0.6.20 software. Samples underwent 
PCR and pyrosequencing in duplicate; any inconsistencies between samples were 
resolved following further repetition.  The extent of methylation at Pvalb CpG sites 
was analysed by repeated-measures ANOVA with region and treatment (PCP/vehicle) 
as factors; significant effects were further investigated by post-hoc t-test.  
3. Results 
During the acquisition trial in the NOR paradigm both groups spent an equal time 
exploring the left and right objects. In the retention trial the vehicle-treated, but not 
PCP-treated, animals spent more time exploring the novel versus the familiar object 
resulting in a significant difference in the discrimination index (vehicle: 0.35±0.04 vs 
PCP: 0.08±0.04; t-test p<0.01). There was no significant difference in locomotor 
activity between the groups (data not shown).  
Brain DNA extracts gave consistent results for methylation at the two CpG sites in the 
Pvalb sequence of interest.  Methylation status of the Pvalb promoter sequence was 
significantly different between the two treatment groups (F=14.82, p=0.001) and 
showed a significant interaction with CpG site (F=11.05, p=0.002) but did not 
significantly differ between or interact with brain region. These findings reflected 
significantly greater methylation in CpG2 from the hippocampus (t=2.778; p=0.015) 
and the PFC (t=2.635; p=0.022) in the PCP group, with mean increases of 16% and 
21% respectively (Fig 1). Mean methylation in the LINE-1 sequence showed no 
statistically significant effect of drug group or region with results as follows for PFC 




 In this preliminary study we have demonstrated a highly significant elevation 
in DNA methylation in one of two CpG sites in the promoter sequence of the PV gene 
in brain tissue taken from rats previously receiving a sub-chronic regime of PCP. It is 
well-established that such PCP administration can induce an enduring deficit of PV-
IR neurons and a reduction in PV gene expression [18], as well as producing 
cognitive deficits, demonstrated here by the reduction in NOR. The increase in Pvalb 
methylation is found not to reflect a general, global increase in DNA methylation, 
being seen in the absence of a significant change in LINE-1 methylation, and 
therefore appears to be a relatively gene-specific consequence of PCP administration. 
The specific increase seen is of a similar magnitude to changes seen in other 
schizophrenia-associated genes in both human [19] and rat brain tissue [20].  
Generally, DNA methylation is inversely related to gene expression, as promoter 
sequence methylation could directly interfere with transcription factor binding sites 
and also indirectly cause gene silencing through methylated DNA binding proteins 
that recruit histone deacetylases, leading to chromatin condensation [21]. 
 The promoter activity of the sequence we have studied has been demonstrated 
[22,23], and the methylation of this sequence has previously been shown to be 
increased following challenge by another neurotoxic factor, that of manganese [13]. 
These authors showed effects of maternal manganese exposure on epigenetic gene 
regulation, with Pvalb promoter hypermethylation and transcript downregulation at 
the weaning stage in the offspring. 
The CpG sites studied here are at the 5’ boundary of a large CpG island with a high 
density of both CpG sites and transcription factor recognition sequences. These 
include multiple binding sites for Nrf2, several close to CpG2 and further CpG sites 
within the CpG island. Thus methylation in this sequence could conceivably modify 
Nrf2 binding and its associated transcriptional activity. Nrf2 has been identified as a 
transcription factor important in antioxidant effects on gene expression [24]. Given 
that the disruptive effects of repeated administration of another NMDA antagonist, 
ketamine, on PV neurons are mediated through oxidative damage [8] and that a 
natural antioxidant and potent activator of Nrf2 can protect against PCP-induced 
cognitive dysfunction [25], these findings provide an intriguing mechanistic link 
between oxidative damage and PV deficits due to PCP administration. 
 Reduced expression of PV is a well-established consequence of multiple 
dosing with NMDA antagonists such as PCP [1, 11]. Thus we suggest that this 
specific Pvalb hypermethylation may contribute to the decreased expression of PV 
mRNA and protein in the hippocampus and frontal cortex that is associated with sub-
chronic PCP administration, although we have not reported corresponding expression 
data in this preliminary communication. However, measures of PV mRNA and 
protein expression do not always correspond [26] and it is not possible to demonstrate 
a causal effect of PCP-induced changes in methylation on PV expression with this 
model. Thus we cannot rule out the possibility that DNA hypermethylation and 
reduced expression of PV are independent consequences of subchronic NMDA 
receptor antagonism by PCP.   
5. Conclusion and Future Perspectives 
This preliminary study demonstrates that sub-chronic PCP administration to 
rats 6 weeks previously, and resulting in a cognitive deficit, can also have a specific 
and enduring effect on DNA methylation in the promoter region of Pvalb. Much more 
needs to be done to fully understand the process and effects of this Pvalb promoter 
hypermethylation. It would be important to determine whether Pvalb methylation 
parallels the time course of PV deficits and the protective effects of antioxidant or 
other pharmacological intervention. We have studied what is likely to be a 
functionally important sequence within the promoter region of Pvalb, but further 
sequences important in transcriptional activity need to be investigated.  Although the 
finding is independent of one measure of global DNA methylation, it may well be that 
other specific genes may also demonstrate changes in DNA methylation, particularly 
those implicated in the GABAergic deficits following PCP administration such as 
those of GAD67 expression [27] and calbindin [28]. Most important would be to 
determine whether hypermethylation of the PV gene occurs in psychotic illness 
including schizophrenia, for which sub-chronic PCP administration can model both 
PV deficits and certain symptoms [29]. 
Executive Summary 
Background  
• Subchronic phencyclidine (PCP) administration to rats can produce enduring 
deficits in the calcium binding protein parvalbumin (PV) in GABAergic neurons; 
these resemble equivalent deficits in schizophrenia. 
• Effects on DNA methylation may contribute to these PV deficits. 
Results 
• We found increased brain DNA methylation at one site in the PV gene 
promoter following subchronic PCP administration to rats. 
• This increase in methylation is specific to a site within a transcription factor 
binding sequence. 
• No differences were found in a global measure of DNA methylation. 
Conclusion 
• PCP sub-chronic administration to rats results in hypermethylation of a 
specific site in the promoter sequence of the PV gene. 
• This hypermethylation may, through effects on transcription, contribute to the 
enduring reduction in PV following PCP administration. 
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Figure 1. Mean percentage of methylation in the Pvalb promoter sequence in 
hippocampal and prefrontal cortex tissue samples in rats undergoing PCP or vehicle. 
Bars represent SEM.*p <0.05. 
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